The Creso Pharma Ltd (ASX: CPH) share price has started the week on a positive note.
In early trade the cannabis company’s shares are up over 9% to 17.5 cents.
Why is the Creso Pharma share price jumping higher?
This morning Creso Pharma announced that it has secured regulatory approval from the Ministry of Agriculture and Animal Feed in Uruguay through its commercial partner Adler Laboratories for its line of animal health products, anibidiol.
According to the release, the company expects the first purchase order for anibidiol 8 (worth A$89,000) to be delivered in the first quarter of 2021. Management notes that this underpins the company’s growing revenue profile in the Latin America (LATAM) region.
What is anibidiol?
Anibidiol is a cannabidiol (CBD) hemp-based complementary feed for pets which the company claims promotes well-being by supporting the immune system and natural response.
The company also claims that it supports behaviour balance, overall vitality, the nervous system, and contributes to the reduction of tiredness and fatigue.
Today’s news means it is the first product of its kind that has been approved for pets in LATAM. Management believes this represents a ground breaking milestone from a regulatory and business perspective.
The approval also represents a key strategic milestone, which broadens the company’s global footprint.
Management believes the LATAM market provides a large opportunity for Creso Pharma and unlocks potential access to over 24 million pets across Uruguay, Argentina, Paraguay and Bolivia and further countries.
Creso Commercial Director, Jorge Wernli, commented: “The approval of anibidiol as the first CBD hemp complementary feed in Uruguay, with a simultaneous purchase order is a major achievement for Creso Pharma. “The Company’s entry into the Latin American market more broadly represents a major strategic development and significant growth opportunity, with potential access to millions of pets across several Latin American countries.”
“We look forward to working with our established, in country representatives to target rapid expansion across the region. We anticipate a number of follow up purchase orders will materialise in the coming months, as we rapidly scale up in Latin America,” he concluded.
This Tiny ASX Stock Could Be the Next Afterpay
One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting…
Because ‘Doc’ Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget ‘buy now pay later’, this stock could be the next hot stock on the ASX.
Doc and his team have published a detailed report on this tiny ASX stock. Find out how you can access what could be the NEXT Afterpay today!
See how you can find out the name of this stock
Returns as of 6th October 2020
More reading
- Creso Pharma (ASX:CPH) share price lower despite supply agreement news
- Creso Pharma and Nuix were among the most traded shares on the ASX last week
- ASX pot stocks have been skyrocketing in December
- Why the Creso Pharma (ASX:CPH) share price crashed 33% lower today
- Why the Creso Pharma (ASX:CPH) share price is rocketing 96% higher today
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post Why the Creso Pharma (ASX:CPH) share price is jumping 9% higher appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/3h2Koci
Leave a Reply